Further hearing loss during osteoporosis treatment with etidronate.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 9799894.
- Also identified by PMC identifier 2360958.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ototoxicity is a rare and disabling complication in bisphosphonate therapy. Here we describe two patients who encountered further hearing loss during oral etidronate treatment for osteoporosis.
Medical subject headings
- Etidronic Acid
- Hearing Loss, Sensorineural
- Osteoporosis, Postmenopausal